Vivus Inc (VVUS): Santosh T Varghese , Chief Medical Officer of Vivus Inc sold 1,553 shares on Jan 13, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $0.95 per share for a total value of $1,474.88.
Currently the company Insiders own 4.5% of VIVUS shares according to the proxy statements.Institutional Investors own 50.37% of VIVUS shares.
VIVUS: On Monday, Apr 11, 2016 heightened volatility was witnessed in VIVUS which led to swings in the share price. The shares opened for trading at $1.67 and hit $1.78 on the upside , eventually ending the session at $1.72, with a gain of 2.38% or 0.04 points. The heightened volatility saw the trading volume jump to 16,81,668 shares. The 52-week high of the share price is $2.65 and the company has a market cap of $179 M . The 52-week low of the share price is at $0.915.
VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.